________________________________________________________________________________________________________________________________

(C) Photo Boehringer Ingelheim - Prof. Dr. Andreas BarnerWe are obliged to more and more move away from animal models

January 2010. Andreas Barner, Chairman of the Board of Managing Directors of Boehringer Ingelheim (BI) evaluates prospects for stem cell technologies in an exclusive interview for readers of B2Bioworld. What are corporate responsibilities specific for this area? Why does his company patent embryonic stem cells?

 

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement -2 pages
- Includes information on IMP, the Institute for Molecular Patholoy which is BI's research arm at Vienna

Full Company License enquire here

Back to section

Related Editorial Articles

Leroy Hood: Thinking Furtherabout Stem Cells

Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan Knowles, Former Member of the Roche Executive Committee and Head of Group Research Leveraging different methods and technologies – clarifying the concept of personalised medicine

GSK: Stem Cell Research Now and in the Future
Patrick Vallance, today President Pharmaceuticals, R&D of GlaxoSmithKline on company strategy and the the role of cancer stem cells

Novo Nordisk: Doing our business a little bit differently than the others in industry
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk on stem cell approaches to diabetes

Merck Serono on stem cell research: Clear away complete confusion of terms
Bernhard Kirschbaum, today Head of Global Research and Early Development for Merck Serono on stem cell research

Drug Testing with Embryonic Stem Cells
- Towards standards for assays

Stem Cells – Failings and Deliveries
Hugh Ilyine, former longtime COO of Stem Cell Sciences looks at clinical trials, reimbursement prospects, and interest of venture capital

TALEs, Zinc Fingers, or Meganucleases
A Practice View from Crop Research and Breeding.
Johan Bottermman, Head of Product Research - Bayer CropScience NV

The Myriad Way
Peter D Meldrum, CEO of the genetics company on battles about patents, cancer chips, and competitors in commercial academia

Handling Suppliers of Mass Spectrometers Delicately
Michael P. Myers, International Centre for Genetic Engineering and Biotechnology, Trieste (IT) tells how he is avoiding to get trapped by manufacturers of mass spectrometers and their strategies to fend off competitors with proprietary data formats

Merck Serono Manufacturing: We have biosimilars coming …
Includes an update on key people moving, e.g. Simon Sturge from Boehringer Ingelheim